Breaking Through Breakthrough Cancer Pain
Breakthrough pain estimates vary, but as many as 50% of patients diagnosed with cancer and chronic pain have pain levels that are not adequately controlled
Read More
Semaglutide Gets FDA Advisory Committee Backing
October 19th 2017Officials with Novo Nordisk have announced that the FDA's Endocrinologic and Metabolic Drugs Advisory Committee (EMDAC) voted 16-0, supporting the approval of once-weekly semaglutide to improve glycemic control in adults with type 2 diabetes.
Read More